Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: An analysis of baseline data from the ORIGIN trial

Diabetes Care

Volumn 35, Issue 4, 2012, Pages 749-753

  Ramachandran, Ambady ^a   Riddle, Matthew C ^b   Kabali, Conrad ^c   Gerstein, Hertzel C ^d  

^a Dr A Ramachandran's Diabetes Hospitals   (India)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DYSGLYCEMIA; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

AGED; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GEOGRAPHY; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC;

EID: 84862110997     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1918     Document Type: Article

References (19)

1. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
4. Kilpatric ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? BMJ 2009;339:1288-1290
5. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518-523
6. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334
7. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-885 (Pubitemid 36929359)
8. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341-346 (Pubitemid 14179538)
9. Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1689-1694
10. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011;154:303-309
11. Cohen RM. A1C: does one size fit all? Diabetes Care 2007;30:2756-2758 (Pubitemid 47547834)
12. Kirk JK, D'Agostino RB Jr, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29:2130-2136 (Pubitemid 44871201)
13. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J; ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32, 32, e1-e6
14. Wolf S, Rave K, Heinemann L, Roggen K. Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the "renal glucose threshold"model. Horm Metab Res 2009;41:600-604
15. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008;112:4284-4291
16. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004;27:931-935 (Pubitemid 38420217)
17. Mori Y. Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents. Nihon Rinsho 2011;69:1505-1514 [in Japanese]
18. Shapiro ET, Van Cauter E, Tillil H, et al. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989;69:571-576 (Pubitemid 19221229)
19. Jeppesen J, Zhou M-Y, Chen Y-DI, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994;17:1093-1099 (Pubitemid 24307442)